Thursday, November 19, 2026

Subscribe

NewsEdition DR CongoDR Congo

DR Congo tests Ebola vaccine against Bundib ऐसा

In Bunia, MSF has launched BRAVO to monitor 20,000 healthcare workers vaccinated with Ervebo against the Bundibugyo strain. The study will assess whether the vaccine reduces infections, severe illness and deaths in the Democratic Republic of the Congo.

Journalists in a newsroom in Kinshasa checking a report on Ebola vaccination, with an abstract screen and blurred documents.

In Bunia, the Ebola response enters a decisive phase

In the east of the Democratic Republic of the Congo, the battle against Ebola is being fought not only in treatment centres. It is also being fought in laboratories, hospitals and field teams, where health workers face the first risks. In Bunia, in Ituri, this reality has prompted the launch of a vaccination study to protect those who treat, monitor and investigate cases involving the virus.

The issue extends beyond the province. Since May 2026, the Ebola virus disease outbreak caused by the Bundibugyo virus has spread beyond its initial focus in Ituri. The World Health Organization now describes intense transmission, amid population movement, insecurity and the persistent humanitarian crisis in eastern Congo.

A trial linked to Congo’s health response

On 19 September 2026, in Bunia, Médecins Sans Frontières and its research centre Epicentre launched BRAVO, a vaccine monitoring project conducted with the Ministry of Health, Africa CDC and the National Institute of Biomedical Research, INRB. The study will follow 20,000 frontline workers in Ituri and North Kivu for nine to 12 months. Three months will be devoted to vaccination, followed by at least six months of participant monitoring.

The vaccine being used is Ervebo, already known in the DRC for its use against Ebola Zaire. But the challenge here is different. The vaccine is authorised against the Zaire strain, not Bundibugyo. The study must therefore assess whether it can reduce infections, severe illness and mortality in this particular outbreak. For now, its effectiveness against Bundibugyo in humans remains uncertain.

This approach has not been improvised. In August 2026, the WHO and Africa CDC approved the allocation of 70,000 doses of Ervebo to the DRC. Of these, 20,000 doses are reserved for a phase 3 clinical trial to understand the vaccine’s impact against the Bundibugyo virus, while 50,000 doses are intended for healthcare workers and other frontline workers.

Why healthcare workers are at the centre of the strategy

The logic is simple. In an Ebola outbreak, healthcare workers are both a bulwark and a target. The WHO says Ervebo is recommended for prevention in outbreaks caused by Ebola Zaire and can be used under a research protocol when investigating whether it also protects against Bundibugyo. The agency stresses that there is not yet sufficient evidence in humans to confirm such protection.

In Bunia, provincial authorities have presented the vaccination of health workers as a way to preserve the health system’s ability to keep functioning over time. This priority has practical implications: without nurses, laboratory staff, contact tracers and clinicians available, the response loses speed and precision.

The governor of Ituri himself received a dose at the launch, in a gesture that was as political as it was public-health-related. The aim was to show that frontline workers must be protected even before science has provided all the answers. The public gesture also conveys a message of reassurance to a population often tested by rumours, fear of isolation and the economic pressure caused by movement restrictions.

A scientific response to an unusually widespread outbreak

The context explains the urgency. As of 12 August 2026, the WHO reported 4,665 confirmed cases and 2,184 deaths in the DRC, with a crude case fatality rate of 46.8%. Ituri remained the epicentre, but the outbreak had already spread to six provinces and 54 health zones. The organisation also noted that infections among healthcare workers continued to rise.

The choice of a research protocol is significant. The WHO considers that, in the absence of a specific vaccine against Bundibugyo, Ervebo should be used only within a well-designed scientific framework, in order to produce robust and comparable data. That is precisely BRAVO’s aim: to document the use of a vaccine that is already available while assessing its actual value in a crisis where every day counts.

This approach also addresses a logistical constraint. Vaccines specifically designed against Bundibugyo are being studied, but are not yet available on a large scale. The WHO says that a candidate such as ChAdOx1 BDBV is in the trial phase, while Ervebo remains the most immediately deployable option.

What is now being monitored in the DRC and the region

For the DRC, the challenge is twofold: break chains of transmission while keeping the healthcare system standing. The launch of BRAVO shows that Kinshasa, Bunia, the INRB, the WHO, Africa CDC and MSF are seeking to bring together the response and the generation of knowledge. In a country where outbreaks can quickly cross borders, this regional dimension matters as much as the treatment of cases.

The continental significance is clear. Central Africa remains exposed to spillover effects, cross-border movement and tensions between health emergencies and security. The Congolese experience could shape future recommendations from the WHO and Africa CDC for future outbreaks caused by different Ebola strains. The real test in the coming weeks will therefore be straightforward: does vaccinating frontline workers provide enough protection to reduce pressure on healthcare facilities, while research progresses towards a vaccine specifically adapted to the Bundibugyo virus?

Automatic translation. Original French version

News quiz

Edition DR CongoDR Congo: the news quiz for 14–15 November

5 questions